Retatrutide (also known by its development code LY3437943) is an investigational weekly injectable medicine being studied for obesity and overweight, and for related conditions.
This article focuses on what human studies have actually reported so far about weight loss with retatrutide—and, just as importantly, what the evidence does not yet show.
Important: Retatrutide is not FDA-approved for weight management as of this writing (US). Any use outside a clinical trial would be off-label/unauthorized. This is educational information, not medical advice.
Short answer
What retatrutide is (and why it’s different)
Retatrutide is sometimes described as a “triple agonist” because it activates three hormone receptors involved in appetite regulation and metabolism:
- GLP-1 (glucagon-like peptide-1) receptor
- GIP (glucose-dependent insulinotropic polypeptide) receptor
- Glucagon receptor
Many currently available obesity medications target one pathway (for example GLP-1). Retatrutide’s investigational hypothesis is that combined signaling across these receptors could drive greater weight loss or different metabolic effects than single- or dual-agonist approaches.
Mechanistically, these systems can influence:
- hunger and satiety signaling in the brain
- gastric emptying and post-meal appetite
- insulin secretion and glucose control
- energy expenditure and lipid metabolism
That said, “triple agonist” is a pharmacology label—not a guarantee of superior real-world outcomes. The relevant question is what trials show.
The key study for weight loss: the phase 2 obesity trial (NEJM)
The most-cited results on retatrutide and weight loss come from a phase 2, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2023.
Who was studied?
Adults were eligible if they had:
- BMI ≥30, or
- BMI 27 to <30 plus at least one weight-related condition
A total of 338 adults were enrolled (about 52% men).
These details matter because weight loss results can differ depending on:
- baseline BMI (higher baseline BMI can change absolute pounds lost)
- presence of diabetes or other metabolic disease
- age, sex, and race/ethnicity
- adherence, side effects, and dose escalation
How the study was designed
Participants were randomized to once-weekly subcutaneous retatrutide at different dose regimens (including different starting doses) or placebo for 48 weeks.
The primary endpoint was percent change in body weight at 24 weeks.
Important note: this is a phase 2 dose-ranging trial. It can provide high-quality evidence about signal and dose response, but it is not designed to answer every long-term question (like cardiovascular outcomes).
What weight loss did participants achieve?
The phase 2 trial reported dose-dependent weight loss.
At 24 weeks (primary endpoint):
- 1 mg: −7.2%
- combined 4 mg groups: −12.9%
- combined 8 mg groups: −17.3%
- 12 mg: −17.5%
- placebo: −1.6%
At 48 weeks (secondary endpoint):
- 1 mg: −8.7%
- combined 4 mg groups: −17.1%
- combined 8 mg groups: −22.8%
- 12 mg: −24.2%
- placebo: −2.1%
These are least-squares mean percentage changes (a statistical approach that accounts for certain baseline factors and missing data patterns).
How many people hit common “clinically meaningful” thresholds?
Trials often report the percent of participants achieving at least:
- ≥5% weight loss (often considered a minimum threshold for metabolic benefit)
- ≥10%
- ≥15%
In this phase 2 trial, at 48 weeks:
4 mg retatrutide:
- ≥5%: 92%
- ≥10%: 75%
- ≥15%: 60%
8 mg retatrutide:
- ≥5%: 100%
- ≥10%: 91%
- ≥15%: 75%
12 mg retatrutide:
- ≥5%: 100%
- ≥10%: 93%
- ≥15%: 83%
Placebo:
- ≥5%: 27%
- ≥10%: 9%
- ≥15%: 2%
How to interpret “24% average weight loss” responsibly
A headline like “24% weight loss” can be both exciting and misleading unless it’s framed precisely.
What it means in this trial context:
- It refers to an average percent reduction in body weight at 48 weeks in one studied dose group.
- Individual responses varied: some people lost more; others lost less.
- This is controlled trial evidence—not an estimate of what will happen for every person.
What it doesn’t mean:
- It doesn’t prove retatrutide is better than every other drug (head-to-head comparisons weren’t the goal).
- It doesn’t tell us the long-term durability beyond ~1 year.
- It doesn’t tell us the tradeoffs for rare adverse events that may require much larger or longer trials to detect.
What about pounds lost?
Percent weight loss is the most standardized measure across studies because it adjusts for different starting weights.
But in practice, people often think in pounds. A 24% reduction could be:
- ~48 lb from a 200 lb baseline
- ~72 lb from a 300 lb baseline
That’s not a promise—just the arithmetic of translating percent loss into pounds.
What side effects were reported in the phase 2 obesity trial?
In the NEJM phase 2 obesity trial, the most common adverse events were gastrointestinal, described as:
- dose-related
- mostly mild-to-moderate
- occurring primarily during dose escalation
Examples included typical GI symptoms seen with GLP-1–based therapies (such as nausea, diarrhea, vomiting, constipation).
Dose escalation seemed to matter
The trial reported that GI events were partially mitigated with a lower starting dose (2 mg vs 4 mg in certain regimens). That aligns with a common pattern in incretin-based therapies: slower titration can improve tolerability for some people.
Heart rate increases were observed
The study reported dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter.
This finding is not unique to retatrutide—some incretin-based therapies can increase heart rate modestly—but the key point is that it is a measured physiologic effect that needs context and longer-term safety evaluation.
What other human studies suggest (especially in type 2 diabetes)
Retatrutide has also been studied in adults with type 2 diabetes (T2D), where weight loss results are often smaller than in people without diabetes—partly due to differences in physiology and background medications.
Phase 2 diabetes trial (Lancet)
In a phase 2 trial conducted in the USA and published in The Lancet (2023), retatrutide was studied across multiple doses in adults with T2D.
At 36 weeks, body weight decreased (dose-dependently) by:
- ~3.19% (0.5 mg)
- ~7.92% (4 mg escalation)
- ~10.37% (4 mg no escalation)
- ~16.81% (8 mg slow escalation)
- ~16.34% (8 mg fast escalation)
- ~16.94% (12 mg escalation)
Placebo was ~3.00% and dulaglutide 1.5 mg was ~2.02% at 36 weeks.
This diabetes trial also reported GI adverse events (mostly mild-to-moderate), and no deaths during the study.
Why include diabetes results in a “weight loss” article?
Because it helps answer a practical question that many readers have:
- “Would results differ if someone has diabetes?”
The current evidence suggests retatrutide can produce robust weight loss even in T2D, though trial populations and endpoints differ.
What studies don’t yet show (the most important limitations)
The weight loss signal in phase 2 trials is strong. But evidence-based decisions depend on what we don’t know yet.
1) Long-term durability beyond ~1 year
The obesity phase 2 trial followed people to 48 weeks.
Obesity is a chronic condition. Two common durability questions remain:
- Does weight loss plateau, continue, or reverse after 1 year?
- If the medication is stopped, how much weight is regained, and how quickly?
For currently approved weight-management drugs, stopping therapy often leads to partial weight regain. Whether retatrutide behaves similarly (and what maintenance strategies look like) requires longer trials.
NIDDK notes generally that prescription weight management medications work best with lifestyle changes and that the duration of treatment depends on benefit and side effects; they also discuss that weight regain can occur after stopping medication.
2) Hard outcomes: cardiovascular events, kidney outcomes, mortality
Weight loss is valuable, but regulators and clinicians also care about outcomes like:
- heart attack and stroke
- heart failure
- kidney disease progression
- hospitalization and mortality
Phase 2 studies are typically not powered to measure these outcomes reliably.
Ongoing and planned phase 3 programs (including outcomes-oriented studies) are designed to address some of these gaps.
3) Rare but serious adverse events
Even a well-run phase 2 trial with a few hundred participants may not detect uncommon but serious risks.
With incretin-based therapies broadly, clinicians often monitor for issues such as:
- gallbladder disease
- pancreatitis (rare)
- severe GI intolerance/dehydration
- potential thyroid-related warnings (class-related considerations vary by product)
Retatrutide’s overall risk profile—especially for rare events—needs larger, longer, phase 3 datasets.
4) Body composition: fat mass vs lean mass
“Weight loss” doesn’t specify what tissue is lost.
Key unanswered questions include:
- How much of the weight loss is fat mass versus lean mass?
- How does retatrutide affect muscle strength and function?
- What happens in older adults or people at risk of sarcopenia?
Some trials include DEXA or other body composition measures, but it’s not yet the core public evidence.
5) Comparisons against other leading medications
The NEJM obesity phase 2 trial was placebo-controlled, which is excellent for measuring whether the drug works versus nothing.
But it does not answer:
- Is retatrutide better than semaglutide 2.4 mg?
- Is it better than tirzepatide in similar populations?
- How do tolerability and discontinuation rates compare?
Head-to-head trials (or carefully matched comparative effectiveness research) are needed for confident comparisons.
6) Generalizability and equity
Trials can underrepresent certain groups or real-world circumstances:
- racial and ethnic diversity
- socioeconomic barriers affecting adherence
- people with complex comorbidities
- those taking multiple interacting medications
The diabetes phase 2 trial, for example, reported a high proportion of White participants.
Broader evidence improves confidence that results apply across populations.
What’s being studied now: phase 3 “TRIUMPH” program (high level)
Retatrutide’s phase 3 development program has been described as the TRIUMPH registrational clinical trials.
A 2026 design paper in Diabetes, Obesity and Metabolism describes four phase 3, multicenter, randomized, double-blind studies evaluating weekly subcutaneous retatrutide vs placebo, with diet and physical activity counseling, in over 5800 participants.
The TRIUMPH program evaluates retatrutide for:
- weight management in obesity
- obesity with obstructive sleep apnea (OSA)
- obesity with knee osteoarthritis (OA)
- obesity with cardiovascular disease (CVD)
It also highlights a “basket trial” concept that nests OSA and OA protocols within weight management trials while allowing independent analysis.
What phase 3 trials can clarify
Compared with phase 2, phase 3 trials can better address:
- longer follow-up (including maintenance)
- safety in larger populations
- subgroup responses (sex, age, comorbidity)
- clinically meaningful secondary endpoints (sleep apnea metrics, OA pain/function)
However, even phase 3 trials have limits—especially if follow-up is not multi-year.
A practical way to read retatrutide “results” headlines
When you see claims like “retatrutide causes 25% weight loss,” use a checklist:
- Which population? Obesity without diabetes vs with diabetes.
- Which time point? 24 weeks, 36 weeks, 48 weeks, 68+ weeks.
- Which dose and titration? Different starting doses can change tolerability and adherence.
- Average vs typical? Mean results can hide variability.
- What’s the comparator? Placebo vs active drug.
- How many participants? A few hundred vs thousands.
- What about discontinuation? Side effects can reduce real-world effectiveness.
What the evidence supports saying (carefully)
Based on the published phase 2 obesity trial:
- Retatrutide produced substantial, dose-dependent average weight loss through 48 weeks.
- The highest dose group reported ~24% mean weight reduction at 48 weeks.
- Many participants achieved ≥15% weight loss at 48 weeks (dose-dependent).
Based on phase 2 diabetes data:
- Retatrutide also produced robust weight loss in adults with T2D (up to ~17% at 36 weeks in some dose regimens).
Across both:
- GI side effects were common and dose-related.
- Heart rate increases were observed (dose-dependent in the obesity phase 2 trial).
What the evidence does not support saying (yet)
Current public data do not prove that retatrutide:
- is safer than other obesity medications
- causes permanent weight loss after stopping
- reduces heart attacks or strokes (hard outcomes) in obesity populations
- works equally well in all demographic and clinical subgroups
- has a fully characterized rare-adverse-event profile
FAQs (investigational, US-focused)
Is retatrutide FDA-approved for weight loss?
Not as of this article’s last update. Retatrutide is investigational in the US.
How is retatrutide taken in trials?
In the major published phase 2 obesity trial, it was given as a once-weekly subcutaneous injection for 48 weeks, with different maintenance doses and titration schedules.
Is 20%+ weight loss “realistic”?
The phase 2 obesity trial reported average weight loss exceeding 20% in some dose groups at 48 weeks. Whether those results translate to typical real-world outcomes depends on future evidence, tolerability, access, and long-term adherence.
Why does placebo lose weight too?
In weight-management trials, placebo groups often receive lifestyle counseling and monitoring, which can lead to modest weight loss.
References (US-focused)
-
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972. PubMed PMID: 37366315. ClinicalTrials.gov: NCT04881760.
-
Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised… phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi:10.1016/S0140-6736(23)01053-X. PubMed PMID: 37385280. ClinicalTrials.gov: NCT04867785.
-
Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026 Jan. PubMed PMID: 41090431.
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription Medications to Treat Overweight & Obesity. Updated 2025. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
-
ClinicalTrials.gov. Retatrutide (LY3437943) study records (examples): NCT04881760 (phase 2 obesity), and multiple TRIUMPH phase 3 records (e.g., NCT05931367, NCT05929066, NCT05929079, NCT06383390). https://clinicaltrials.gov/